Innovative design concepts in tumor-targeting peptide-drug conjugates\: Insights into emerging applications
10
作者人数
5
被引次数
来源:Crossref,截至 2026-10-20
作者
- 1 Ruirong Tan 第一作者
- 2 Zhenya Yang
- 3 Jun Xie
四川大学华西医院
- 4 Zijun Wu
- 5 Shanshan Guo
- 6 Li Li
- 7 Zhujun Yin
- 8 Hua Hua
- 9 Miao Liu
- 10 Rui Li
参考文献 共 84 条
- 1 Antibody-drug conjugates in HER2-positive breast cancer 10.1097/cm9.0000000000001932
- 2 A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy 10.3389/fphar.2023.1274088
- 3 Progress of antibody-drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies 10.1007/s13346-024-01564-3
- 4 Neoantigens in precision cancer immunotherapy: From identification to clinical applications 10.1097/cm9.0000000000002181
- 5 Antibody–drug conjugates come of age in oncology 10.1038/s41573-023-00709-2
- 6 Unlocking the potential of antibody–drug conjugates for cancer therapy 10.1038/s41571-021-00470-8
- 7 Current status of surgical treatment of rectal cancer in China 10.1097/cm9.0000000000001076
- 8 Small molecule–and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment 10.1002/psc.3561
- 9 Small molecule-drug conjugates: Opportunities for the development of targeted anticancer drugs 10.1002/cmdc.202300720
- 10 Peptide-drug conjugates: A new hope for cancer management 10.3390/molecules27217232
- 11 Peptide-drug conjugates: Design, chemistry, and drug delivery system as a novel cancer theranostic 10.1021/acsptsci.3c00269
- 12 Tumor-penetrating peptide for systemic targeting of Tenascin-C 10.1038/s41598-020-62760-y
- 13 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors 10.1080/17474124.2019.1685381
- 14 Lutetium-177 DOTATATE: A practical review 10.1016/j.prro.2022.02.002
- 15 NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial 10.1016/s1470-2045(18)30193-1
- 16 Phase I study of 99mTc-ADAPT6, a scaffold protein–based probe for visualization of HER2 expression in breast cancer 10.2967/jnumed.120.248799
- 17 Affibody-derived drug conjugates targeting HER2: Effect of drug load on cytotoxicity and biodistribution 10.3390/pharmaceutics13030430
- 18 Morphological transformation enhances tumor retention by regulating the self-assembly of doxorubicin-peptide conjugates 10.7150/thno.45088
- 19 Gemcitabine peptide-based conjugates and their application in targeted tumor therapy 10.3390/molecules26020364
- 20 Neurodegenerative disease and brain delivery of therapeutics: Bridging the gap using dendrimers
- 21 Berberine prevents diabetic retinopathy through inhibiting HIF-1α/VEGF/ NF-κB pathway in db/db mice
- 22 Biomimetic dendrimer–peptide conjugates for early multi-target therapy of Alzheimer’s disease by inflammatory microenvironment modulation
- 23 The coming of age of cyclic peptide drugs: An update on discovery technologies 10.1080/17460441.2024.2367024
- 24 EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma 10.1002/ijc.31405
- 25 BT8009; a nectin-4 targeting bicycle toxin conjugate for treatment of solid tumors 10.1158/1535-7163.mct-21-0875
- 26 Peptides as multifunctional players in cancer therapy 10.1038/s12276-023-01016-x
- 27 New design of helix bundle peptide−polymer conjugates 10.1021/bm800113g
- 28 Peptide–drug conjugates with different linkers for cancer therapy 10.1021/acs.jmedchem.0c01530
- 29 Peptide–drug conjugates (PDCs): A novel trend of research and development on targeted therapy, hype or hope? 10.1016/j.apsb.2022.07.020
- 30 Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2 10.1038/bjp.2008.260
- 31 Learn from antibody–drug conjugates: Consideration in the future construction of peptide-drug conjugates for cancer therapy 10.1186/s40164-022-00347-1
- 32 Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer 10.1080/10717544.2018.1435746
- 33 Modulating paclitaxel bioavailability for targeting prostate cancer 10.1016/j.bmc.2007.04.029
- 34 Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice
- 35 Organic carbamates in drug design and medicinal chemistry 10.1021/jm501371s
- 36 The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity 10.1002/cmdc.201000478
- 37 More than toxins—current prospects in designing the next generation of antibody drug conjugates 10.31083/j.fbl2708240
- 38 Regulated cell death in cancer: From pathogenesis to treatment 10.1097/cm9.0000000000002239
- 39 Proteolysis-Targeting Chimeras (PROTACs) in cancer therapy: Present and future 10.3390/molecules27248828
- 40 ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155) 10.1200/jco.2018.36.15_suppl.5503
- 41 Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study 10.1200/jco.2023.41.16_suppl.3089
- 42 Supramolecular “Trojan Horse” for nuclear delivery of dual anticancer drugs 10.1021/jacs.6b12322
- 43 Enzyme-instructed molecular self-assembly confers nanofibers and a supramolecular hydrogel of taxol derivative 10.1021/ja904411z
- 44 Camptothecin’s journey from discovery to WHO Essential Medicine: Fifty years of promise 10.1016/j.ejmech.2021.113639
- 45 Design of controlled drug delivery system based on disulfide cleavage trigger 10.1021/jp507763a
- 46 Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel 10.1038/s41551-020-0597-7
- 47 Selective neuropeptide Y conjugates with maximized carborane loading as promising boron delivery agents for boron neutron capture therapy 10.1021/acs.jmedchem.9b01136
- 48 Progress and future directions with peptide–drug conjugates for targeted cancer therapy 10.3390/molecules26196042
- 49 Peptide–drug conjugates: An emerging direction for the next generation of peptide therapeutics 10.1021/acs.jmedchem.3c01835
- 50 Peptide drugs: A new direction in cancer immunotherapy
- 51 Active targeting gold nanoparticle for chemotherapy drug delivery: A Review
- 52 Peptide–drug conjugate-based nanocombination actualizes breast cancer treatment by maytansinoid and photothermia with the assistance of fluorescent and photoacoustic images 10.1021/acs.nanolett.9b00770
- 53 Enzymatic hydrogelation of small molecules 10.1021/ar7001914
- 54 Supramolecular hydrogelators and hydrogels: From soft matter to molecular biomaterials 10.1021/acs.chemrev.5b00299
- 55 A peptide-based material for therapeutic carbon monoxide delivery 10.1039/c2sm25785h
- 56 Self-assembly behaviours of peptide–drug conjugates: Influence of multiple factors on aggregate morphology and potential self-assembly mechanism 10.1098/rsos.172040
- 57 Supramolecular crafting of self-assembling camptothecin prodrugs with enhanced efficacy against primary cancer cells 10.7150/thno.15420
- 58 Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery 10.1016/j.actbio.2020.05.026
- 59 Type I collagen is thermally unstable at body temperature 10.1073/pnas.032307099
- 60 Enzyme-triggered self-assembly of peptide hydrogels via reversed hydrolysis 10.1021/ja056549l
- 61 Capilliposide from Lysimachia capillipes promotes terminal differentiations and reverses paclitaxel resistance in A2780T cells of human ovarian cancer by regulating Fos/Jun pathway
- 62 Supramolecular Self-assembly of a Model Hydrogelator: Characterization of Fiber Formation and Morphology 10.3390/gels2040027
- 63 Dephosphorylation of D-peptide derivatives to form biofunctional, supramolecular nanofibers/hydrogels and their potential applications for intracellular imaging and intratumoral chemotherapy 10.1021/ja404215g
- 64 Synthesis and biological characterization of monomeric and tetrameric RGD-cryptophycin conjugates 10.1002/chem.201905437
- 65 The ligand binding mechanism to purine nucleoside phosphorylase elucidated via molecular dynamics and machine learning 10.1038/ncomms7155
- 66 A designed cyclic peptide based on trastuzumab used to construct peptide-drug conjugates for its HER2-targeting ability 10.1016/j.bioorg.2021.105453
- 67 Multivalency increases the binding strength of RGD peptidomimetic-paclitaxel conjugates to integrin αVβ3 10.1002/chem.201703093
- 68 Effects of a novel cyclic RGD peptidomimetic on cell proliferation, migration and angiogenic activity in human endothelial cells 10.1186/2045-824x-6-11
- 69 In vivo tumor growth inhibition and antiangiogenic effect of cyclic NGR peptide-daunorubicin conjugates developed for targeted drug delivery 10.1007/s12253-019-00773-3
- 70 Peptide drug conjugates and their role in cancer therapy 10.3390/ijms24010829
- 71 Aldehyde PEGylation of laccase from trametes versicolor in route to increase its stability: Effect on enzymatic activity 10.1002/jmr.2405
- 72 Anti-inflammatory effects of PEGylated human adrenomedullin in a mouse DSS-induced colitis model 10.1002/ddr.21383
- 73 Tumor vasculature-targeting PEGylated peptide–drug conjugate prodrug nanoparticles improve chemotherapy and prevent tumor metastasis 10.1016/j.ejmech.2021.113430
- 74 Synthesis and preclinical evaluation of a novel, selective 111In-labelled aminoproline-RGD-peptide for non-invasive melanoma tumor imaging 10.1039/c5md00301f
- 75 New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration 10.1021/jm9016637
- 76 Targeting the hypoxic and acidic tumor microenvironment with pH-sensitive peptides 10.3390/cells10030541
- 77 Peptides as a platform for targeted therapeutics for cancer: Peptide–drug conjugates (PDCs) 10.1039/d0cs00556h
- 78 A brand new era of cancer immunotherapy: Breakthroughs and challenges 10.1097/cm9.0000000000001490
- 79 New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: Mechanisms and therapeutic opportunities 10.1186/s40164-022-00356-0
- 80 Research advances in peptide–drug conjugates 10.1016/j.apsb.2023.02.013
- 81 The role of the symbiotic microecosystem in cancer: Gut microbiota, metabolome, and host immunome 10.3389/fimmu.2023.1235827
- 82 Molecular mechanisms of anti-cancer bioactivities of seaweed polysaccharides
- 83 Renovation of old drugs’–can peptide drug conjugates lead the post-ADC era? 10.1071/ch22252
- 84 Abnormal O-GlcNAcylation of Pax3 occurring from hyperglycemia-induced neural tube defects is ameliorated by carnosine but not folic acid in chicken embryos 10.1007/s12035-015-9581-8
数据来源
- 论文信息:
- 中华医学期刊网、Crossref
- 作者名单:
- Crossref
- 被引次数:
- Crossref,截至 2026-10-20
- 参考文献:
- Crossref
论文的著作权归作者与出版方所有,本站只整理公开的题录信息并附原文链接,不构成任何医疗建议。